TY - JOUR AU - Nychytailo, M.Yu. PY - 2019/06/29 Y2 - 2024/03/29 TI - Sorbilact® as a mean of pharmacological correction of postoperative ileus JF - EMERGENCY MEDICINE JA - ЕМ VL - IS - 4.99 SE - Scientific Review DO - 10.22141/2224-0586.4.99.2019.173929 UR - https://emergency.zaslavsky.com.ua/index.php/journal/article/view/1136 SP - 30-37 AB - Postoperative ileus (POI) occurs after many surgical interventions, but most often after abdominal operations — with a frequency of 10–30 %. This complication increases postoperative morbidity, duration of hospitalization and cost of treatment. In the Cochrane systematic review, it was shown that none of the routinely used prokinetic drugs (neostigmine, metoclopramide, erythromycin) or laxatives reduce the duration of POI (level of evidence Ia). At the same time, the application of neostigmine is associated with the risk of side effects in almost all organs and systems. The use of metoclopramide was restricted by the European Medicines Agency due to the risk for developing severe neurological side effects. Both drugs are prescribed too late, on days 3–5 after surgery, often when POI is already developed. Under these conditions, the Ukrainian infusion preparation Sorbilact®, with sorbitol as the main active ingredient, deserves attention. Many clinical studies have demonstrated its ability to reduce the duration of POI by 1.5–2 times. At the same time, Sorbilaсt® had clinical bene­fits by shortening the interval to the appearance of audible bowel sounds on auscultation, passage of flatus and stool. The obtained data were confirmed instrumentally using computer pneumokinesography and ultrasonography. Sorbilact® can be administered in the first hours after surgery, or even directly during it. Both preventive and therapeutic goals can be pursued. In the cited clinical studies, Sorbilact® did not cause any side effects. Due to the fact that sorbitol, which is a component of Sorbilact®, is converted into fructose in the body, the drug is not prescribed to individuals with hereditary fructose intolerance. ER -